Tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib and dasatinib are now well-established first-line treatments for CML with durable responses. 1, 2 The role of allogeneic stem cell transplant (alloSCT) has consequently altered in the TKI era; however, it remains an important option for selected patients with TKI resistance or inadequate disease control, including some BCR-ABL mutation-mediated resistance to TKI therapy. 3, 4 Controversies such as who should receive alloSCT and the optimal timing of alloSCT are now more important. This study aimed to examine the differences in outcomes and describe temporal trends in patients having alloSCT for CML after TKI failure.
Inclusion criteria for this study were an alloSCT for CML in Australia and New Zealand between 2000-2010 for recipients aged 16 years and above, recorded on the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR). 5 We compared the 2005-2010 group during which time TKIs were readily available with the 2000-2004 group during which time TKIs were less available, and analysed trends in patient, disease and transplant details. Patient consent for data submission to the ABMTRR is obtained by individual participating institutions. This study was approved by the ABMTRR Steering Committee. Further information for the 2005-2010 group was asked using a customised spreadsheet questionnaire with a limited number of questions designed to not overburden the corresponding data managers at transplant centres. Less detailed data from the ABMTRR database were used for the 2000-2004 group.
Resistance to TKI was defined as a patient initially responding to TKI, but proceeding to alloSCT because of disease progression or failure to achieve complete cytogenetic remission. Diagnoses of acute (up to 100 days post alloSCT) and chronic (beyond 100 days post alloSCT) GvHD were made at local institutions. Relapse was defined by any level of relapse determined by the treating hospital at the haematologic, cytogenetic or molecular level.
Overall survival (OS) was calculated using Kaplan-Meier product limit estimates, and differences between groups were assessed with the log-rank test. Multivariate Cox regression analyses were performed to establish whether OS was influenced by sex (male), age (440 years), length of time from diagnosis to alloSCT (2 years or more), unrelated donor, advanced stage disease, myeloablative conditioning, cell source bone marrow, resistance to TKIs pre-transplant and year of alloSCT. Cumulative incidence of GvHD, non-relapse mortality and relapse were calculated using death from other causes as competing risks, and stated with weighted upper and lower 95% confidence intervals. Five-year survival probabilities were stated with weighted upper and lower 95% confidence intervals. Cumulative incidence curves were constructed using Number Cruncher Statistical System in first, second or third chronic phase, and 21 (26%) in advanced phase. Imatinib, dasatinib or nilotinib were administered to 73 (91%) before alloSCT, and 71 (88%) had TKI resistance/ intolerance. Donor source was sibling in 40 (50%), with 64 (80%) peripheral blood grafts, and the majority of 66 (83%) having myeloablative conditioning. Figure 1 displays clinical outcomes. Probability of OS was 61% at 5 years post alloSCT. Probability of OS post alloSCT for chronic versus accelerated phase or blast crisis (55% versus 76%, P = 0.1), and probability of OS for first chronic phase versus second or third chronic phase (56% versus 55%, P = 0.6), were not statistically significant. None of the nominated single variables was found to have a statistically significant effect on OS. Leukaemia-free survival at 5 years post alloSCT was 45.7% (95% confidence interval, 33.0-58.4). Cumulative incidences of grade II-IV acute GvHD was 48% at 100 days post alloSCT, all grades of chronic GvHD 61% at 2 years, non-relapse mortality 13.8% at 100 days and 22.6% at 1 year post alloSCT, and relapse of CML 7.7% at 6 months and 14.1% at 1 year post alloSCT. Post-alloSCT treatment consisted of donor lymphocyte infusions (DLIs) in 7 (9%) and TKIs in 19 (24%), two of whom were intolerant to TKIs before alloSCT and the majority of patients were in chronic phase pre-alloSCT (15 chronic Analysis of the 2005-2010 group using combined risk factors from the European Society for Blood and Marrow Transplantation (EBMT) score 6 showed patients aged ⩽ 40 with HLA-identical siblings versus patients aged 440 with unrelated donors had a higher 5-year survival (72.5% versus 37.6%, P = 0.04). There were no statistically significant differences in 5-year survival for other combinations of risk factors, nor of patients with low (0-3) versus high (4-6) EBMT scores. In the 2000-2004 group, analysis using combined risk factors showed significant differences in 5-year survival for HLA-identical siblings in first chronic phase versus unrelated donors in accelerated or blast phase (71.3% versus 26.0%, P o 0.001), age ⩽ 40 with HLA-identical siblings versus age 440 with unrelated donors (79.2% versus 43.9%, P = 0.001), females with identical donors versus males with unrelated donors (64.8% versus 39.4%, P = 0.02), and low (0-3) versus high (3-5) EBMT scores (69.5% versus 41.9%, P o0.001).
The long-term survival of 60.9% at 5 years in this 2005-2010 group of patients is very encouraging, particularly as the group had failed TKIs and contained a greater proportion of older, advanced disease patients and unrelated donors, which often have reduced performance status, greater transplantrelated mortality and higher relapse rates. 7 This highlights the value of alloSCT in specific cases of CML, and these results appear to enhance and support the data from similar studies, 1, 8, 9 supporting consideration of alloSCT in specific patients. Patients destined to fail TKI therapy at a relatively early stage as discovered by molecular monitoring and mutation analysis, and those presenting in advanced disease seem optimal for alloSCT.
Timing of alloSCT with regard to CML disease status is important, as inferior outcomes have been demonstrated in advanced disease, particularly blast crisis. 7 There was no statistically significant difference in survival between our groups with chronic phase versus accelerated phase/blast transformation, which does not imply that one group has better survival than the other, but rather that disease status at transplant did not hold such an influence in the 2005-2010 group. Current European guidelines recommend patients in accelerated phase CML be considered for alloSCT unless they achieve an optimal response to TKIs. 10 For CML in blast crisis, TKI combined with alloSCT is superior to TKI therapy alone. 9 The relatively high rate of GvHD in our cohort may reflect physician concerns of disease relapse, with more rapid weaning of immunosuppression to promote GvL effects, consistent with previous studies showing increased probability of remission associated with grade II-IV acute GvHD or any degree of chronic GvHD. 11 We noted with interest the survival differences with combined risk factors. The only statistically significant difference in the 2005-2010 group was patients aged ⩽ 40 with HLA-identical siblings having a higher 5-year survival compared with patients aged 440 with unrelated donors. In contrast, analysis of combined risk factors in the earlier 2000-2004 group showed statistically significant differences with many different combinations. This suggests that in the TKI era, patients aged 440 with unrelated donors may have lower survival post alloSCT, although other risk factors may have less influence on survival. Whether this is attributable to TKI therapy before alloSCT or other factors is uncertain and ultimately further experience is needed. No negative outcomes have been documented if CML patients received TKI before alloSCT. 12 Post-alloSCT treatment in our cohort comprised TKIs in 19/80 patients (14 of these had relapsed) and DLIs at molecular relapse in 7(9%) of cases. TKIs have been used for initial treatment 8, 13 with persisting disease or the development of molecular positivity post alloSCT, and there are encouraging long-term results of DLIs that are superior to TKIs alone, 14 though potential negative effects associated with GvHD need to be considered.
Efforts are ongoing to reduce treatment-related mortality and morbidity. Our results showed more reduced intensity conditioning in the recent cohort, consistent with other reports showing acceptable toxicity and survival. 15 Other strategies include using anti-T-cell globulins, improvements in HLA matching, cord blood and related haploidentical hematopoietic stem cells, and improved supportive care, allowing additional patients to be considered for alloSCT.
We highlight the fact that alloSCT remains an important salvage modality for patients losing disease control with TKIs and that ongoing improvements continue, so that more challenging cases can have this treatment. 
